TFM
ARQT icon

TFC Financial Management’s Arcutis Biotherapeutics ARQT Stock Holding History

TFC Financial Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Hold
1
– – ﹤0.01% 1018
2026
Q1 		$24 Buy
+1
New +$26 ﹤0.01% 985

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TFC Financial Management's ARQT Position: Q2 2026 in Review

TFC Financial Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 1 share worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #1018.

TFC Financial Management first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • TFC Financial Management held 1 share of Arcutis Biotherapeutics worth $27 as of Q2 2026.
  • TFC Financial Management left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of TFC Financial Management's portfolio in Q2 2026, its #1018 holding.
  • TFC Financial Management first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.